To Study the Effect of Statins on Proteinuria in CKD Progression in A Tertiary Care Hospital (Code-T0088)

Introduction: Chronic kidney disease (CKD) is a progressive condition characterized by a decline in renal function and is often associated with proteinuria, which exacerbates disease progression. Statins, widely used for their lipid-lowering effects, have demonstrated potential renoprotective effects, including reducing proteinuria. This study evaluates the impact of statins on proteinuria and their role in slowing CKD progression in a tertiary care hospital setting.

Aims & Objective:

• To study the effect of Statins on proteinuria among patients with CKD  Stage 3^rd  4^th& 5^th
• To compare the outcome of Statin on the disease [ CKD] progression in renal functions

Methods: This prospective study was conducted at a tertiary care hospital, involving 200 CKD patients divided into two groups: those receiving statins (Group A) and those not receiving statins (Group B). Inclusion criteria included CKD patients with proteinuria and eGFR levels between 15 and 60 mL/min/1.73 m². Proteinuria levels were measured using urine protein-to-creatinine ratio (UPCR), and renal function was assessed via eGFR over a 12-month follow-up period. Statistical analyses were conducted to compare proteinuria levels and CKD progression between the two groups.

Results: Group A demonstrated a significant reduction in proteinuria (p < 0.001) and a slower decline in eGFR compared to Group B (p = 0.002). The renoprotective effect of statins was more pronounced in patients with higher baseline proteinuria levels.

Conclusion: Statin therapy significantly reduces proteinuria and slows CKD progression, highlighting its potential as an adjunctive treatment in CKD management. Further studies are warranted to explore the long-term benefits of statins in CKD populations.

Keywords: Chronic kidney disease; Proteinuria; Statins; CKD progression; Renoprotection; eGFR.